SLC5A2 and diabetic kidney disease: Table 2 lists the main clinical trials of SGLT2 inhibitors assessing cardiovascular and renal outcomes, with some of them conducted in patients also having diabetic kidney disease (DKD) and heart failure with reduced ejection fraction (HFrEF).